Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 4/20 | 0.32 |
| ▸ | ACHE | P22303 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638561 | 0.90 | POLB (0.40) | HSD11B1HSD11B2POLBALDH1A1TSHR | |
| SCHEMBL23638642 | 0.83 | POLB (0.42) | HSD11B1HSD11B2POLBALDH1A1TSHR | |
| SCHEMBL23638713 | 0.79 | — | — | |
| SCHEMBL23638716 | 0.73 | POLB (0.44) | HSD11B1HSD11B2POLBALDH1A1TSHR | |
| SCHEMBL14030286 | 0.71 | POLB (0.55) | HSD11B1HSD11B2POLBALDH1A1TSHR | |
| SCHEMBL14030255 | 0.69 | POLB (0.58) | HSD11B1HSD11B2POLBALDH1A1TSHR | |
| SCHEMBL23638651 | 0.69 | — | — | |
| SCHEMBL8367476 | 0.66 | KDM4E (0.47) | POLBTSHRHPGDKDM4E | |
| SCHEMBL14048238 | 0.65 | POLB (0.47) | POLBTSHRKDM4E | |
| SCHEMBL7768463 | 0.65 | MAPT (0.46) | POLBTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | HSD11B1 1901/4885HSD11B2 2684/4885POLB 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.